TapImmune Commences Trading on the Nasdaq Capital Market

Jacksonville, Fla. – November 8, 2016 – TapImmune, Inc., (NASDAQ: TPIV), an immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, today announced that its common stock has commenced trading on The Nasdaq Capital Market from the opening of market today. The company’s…

TapImmune Announces Commercialization Pathway For Its HER2neu Vaccine

Jacksonville FL, November 1, 2016 – TapImmune, Inc. (OTCMKTS: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, is providing an update on the progression of a HER2neu vaccine into clinical trials. The vaccine (TPIV 110) consists of 4…

TapImmune Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market

JACKSONVILLE, Florida, September 15, 2016 / TapImmune Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, announced today that its Board of Directors has approved a 1-for-12 reverse stock split of the Company’s authorized, issued, and outstanding common…